title: Molecular Pathways: The eIF4F Translation Initiation Complex-New Opportunities for Cancer Treatment.
abstract: The eIF4F complex regulates the cap-dependent mRNA translation process. It is becoming increasingly evident that aberrant activity of this complex is observed in many cancers, leading to the selective synthesis of proteins involved in tumor growth and metastasis. The selective translation of cellular mRNAs controlled by this complex also contributes to resistance to cancer treatments, and downregulation of the eIF4F complex components can restore sensitivity to various cancer therapies. Here, we review the contribution of the eIF4F complex to tumorigenesis, with a focus on its role in chemoresistance as well as the promising use of new small-molecule inhibitors of the complex, including flavaglines/rocaglates, hippuristanol, and pateamine A. Clin Cancer Res; 23(1); 21-25. ©2016 AACR.
authors: Institut Curie, PSL Research University, CNRS UMR 3348, Orsay, France.|Université Paris Sud, Université Paris-Saclay, CNRS UMR 3348, Orsay, France.|Equipe Labellisée Ligue Contre le Cancer, Paris, France.
authors: Hélène
authors: H
authors: Malka-Mahieu
authors: Institut Curie, PSL Research University, CNRS UMR 3348, Orsay, France.|Université Paris Sud, Université Paris-Saclay, CNRS UMR 3348, Orsay, France.|Equipe Labellisée Ligue Contre le Cancer, Paris, France.
authors: Michelle
authors: M
authors: Newman
authors: Laboratory of Therapeutic Innovation (UMR 7200), Faculty of Pharmacy, University of Strasbourg-CNRS, Illkirch, France.|Sino-French Joint Lab of Food Nutrition/Safety and Medicinal Chemistry, College of Biotechnology, Tianjin University of Science and Technology, Tianjin, China.
authors: Laurent
authors: L
authors: Désaubry
authors: INSERM U981, Villejuif, France. stephan.vagner@curie.fr caroline.robert@gustaveroussy.fr.|Institut de Cancérologie Gustave Roussy, Villejuif, France.|Université Paris-Sud, Kremlin-Bicêtre, France.
authors: Caroline
authors: C
authors: Robert
authors: Institut Curie, PSL Research University, CNRS UMR 3348, Orsay, France. stephan.vagner@curie.fr caroline.robert@gustaveroussy.fr.|Université Paris Sud, Université Paris-Saclay, CNRS UMR 3348, Orsay, France.|Equipe Labellisée Ligue Contre le Cancer, Paris, France.|INSERM U981, Villejuif, France.|Institut de Cancérologie Gustave Roussy, Villejuif, France.
authors: Stéphan
authors: S
authors: Vagner
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D002471:Cell Transformation, Neoplastic / Q000235:genetics / Q000378:metabolism; D019008:Drug Resistance, Neoplasm / Q000187:drug effects / Q000235:genetics; D039562:Eukaryotic Initiation Factor-4F / Q000378:metabolism*; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D058990:Molecular Targeted Therapy; D046912:Multiprotein Complexes / Q000378:metabolism*; D009369:Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism*; D014176:Protein Biosynthesis; D015398:Signal Transduction / Q000187:drug effects; D057170:Translational Research, Biomedical
chemical_list: D000970:Antineoplastic Agents; D039562:Eukaryotic Initiation Factor-4F; D046912:Multiprotein Complexes